To develop and validate radiomics models on non-enhanced CT for discrimination of arteriovenous malformation (AVM) related hematomas from hypertensive intracerebral hematomas.
A total of 571 patients with acute intraparenchymal hematomas and baseline non-enhanced CT scans were retrospectively analyzed, including 297 cases of AVM related hematomas and 274 cases of hypertensive intracerebral hematomas. The patients were divided into training and validation cohorts in a 7:3 ratio with a random seed. A total of 1,688 radiomics features of hematomas were extracted from non-enhanced CT. Then, the least absolute shrinkage and selection operator (LASSO) regression was applied to select features and construct the radiomics models. In this study, a radiomics-based model was constructed that based on the radiomics features only. Furthermore, a combined model was constructed using radiomics features, clinical characteristics and radiological signs by radiologists’ evaluation. In addition, we compared predictive performance of the two models for discrimination of AVM related hematomas from hypertensive intracerebral hematomas.
A total of 67 radiomics features were selected to establish radiomics signature via LASSO regression. The radiomics-based model was constructed with 2 classifiers, support vector machine (SVM) and logistic regression (LR). AUCs of the radiomics-based model in the training set were 0.894 and 0.904, in validation set were 0.774 and 0.782 in SVM classifier and LR classifier, respectively. AUCs of the combined model (combined with radiomics, age and calcification) in the training set were 0.976 and 0.981, in validation set were 0.896 and 0.907 in SVM classifier and LR classifier, respectively. The combined model showed greater AUCs than radiomics-based model in both training set and validation set.
The combined model using radiomics, age and calcification showed a satisfactory predictive performance for discrimination of AVM related hematomas from hypertensive intracerebral hematomas and hold great potential for personalized clinical decision.